Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vaxon Biotech has said that the European Medicines Agency has granted orphan drug status to Vx-001, its treatment for TERTpositive non-small cell lung cancer in HLA-A2 positive patients.
Subscribe to our email newsletter
The European Medicines Agency’s (EMEA) orphan medicinal product designation is intended to promote the development of drugs which may provide significant benefits to patients suffering from life-threatening or very serious conditions which affect less than five in 10,000 persons in the European community.
In the very short term, the company’s goal is to consolidate its initial clinical results for Vx- 001 by launching Phase II trials in non-small cell lung cancer and hepatocarcinoma and then tackle new oncological indications.
Nadege Le Roux, director, drug development at Vaxon, said: “There is a real need for innovative new treatment options (such as Vx-001) for patients with lung cancer. This orphan drug designation is a significant step forward in Vx-001’s clinical development plan and offers potential benefits for approval of the drug in the European Union. These patients deserve the hope of greater life expectancy and better quality of life through innovative therapeutics.”